TRDA
NASDAQ
US
Entrada Therapeutics, Inc. - Common Stock
$13.15
▼ $-0.33
(-2.45%)
Vol 178K
2
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$392.9M
ROE
-26.4%
Margin
-168.2%
D/E
0.00
Beta
-0.14
52W
$5–$19
Wall Street Consensus
13 analysts · Apr 20265
Strong Buy
7
Buy
1
Hold
0
Sell
0
Strong Sell
92.3%
Buy Rating
Price Chart
Similar Stocks
CBIO
Crescent Biopharma Inc
$164.8M
ZURA
Zura Bio Ltd
$340.7M
UPB
Upstream Bio Inc
$1.5B
RIGL
Rigel Pharmaceuticals Inc
P/E 6.9
$777.4M
LRMR
Larimar Therapeutics Inc
$326.1M
VSTM
Verastem Inc
$581.5M
LYEL
Lyell Immunopharma Inc
$653.9M
FDMT
4D Molecular Therapeutics Inc
$428.5M
IMMX
Immix Biopharma Inc
$275.6M
ABSI
Absci Corp
$524.8M
Earnings
Beat rate: 50.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Dec 2025 | $-1.17 | $-0.94 | +$0.23 |
| Sep 2025 | $-0.96 | $-1.06 | $-0.10 |
| Jun 2025 | $-0.86 | $-1.04 | $-0.18 |
| Mar 2025 | $-0.80 | $-0.42 | +$0.38 |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -17.8% | -17.8% | -17.8% | -17.8% | -26.4% | -26.4% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -2210.4% | -92.3% | -92.3% | -92.3% | -168.2% | -168.2% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 18.64 | 18.64 | 18.64 | 18.64 | 14.08 | 14.08 |
Key Ratios
ROA (TTM)
-22.1%
P/S (TTM)
6.39
P/B
1.5
EPS (TTM)
$-2.50
CF/Share
$-0.58
52W High
$18.76
52W Low
$4.93
$4.93
52-Week Range
$18.76
How does TRDA compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
TRDA valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
6.4
▼
50%
below
peers
(12.9)
vs Peers
vs Industry
Undervalued
P/B ratio
1.5
▼
39%
below
peers
(2.5)
vs Peers
vs Industry
Pricier
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
TRDA profitability vs Biotechnology peers
ROE
-26.4%
▲
61%
above
peers
(-67.3%)
vs Peers
vs Industry
Top tier
Net margin
-168.2%
▲
41%
above
peers
(-286.8%)
vs Peers
vs Industry
Below avg
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-22.1%
▲
53%
above
peers
(-46.7%)
vs Peers
vs Industry
Top tier
TRDA financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
14.1
▲
217%
above
peers
(4.4)
vs Peers
vs Industry
Strong liquidity
Beta
-0.1
▼
115%
below
peers
(1.0)
vs Peers
vs Industry
More volatile
TRDA fundamentals radar
TRDA
Peer median
Industry
TRDA profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
TRDA vs peers: key metrics
Latest News
No related news yet